Fig. 2

Flow cytometric analysis of microglia surface markers in SLE-serum, healthy-serum and ACSF-treated mice (n = 16, 14 and 10). a Cells were defined by gate R1 to eliminate unwanted events, such as cell debris. b Microglias were identified by their CD45^lowCD11b + phenotype (R2). c Isotype for MHCII was used to define the gating of M1 cells. In this population, SLE-serum led to a significantly increased percentage of MHC-II + CD45^lowCD11b⁺ cells. d Isotype for CD206 was used to define the gating of M2 cells. In contrast, percentage of CD206⁺ was not significantly changed by SLE-serum treatment in the CD45^lowCD11b⁺ cells. Bars represent the mean ± SEM of mice groups received injection of SLE-serum, healthy-serum or ACSF. Pictures of c and d show representative histogram and flow dot plots of MHC-II and CD206 expression, respectively, in the CD45^lowCD11b⁺ population. *p < 0.05; **p < 0.01